Gait changes following a SEP in IC patients

  • Research type

    Research Study

  • Full title

    Does a 12-week Supervised Exercise Programme affect gait in individuals with intermittent claudication?

  • IRAS ID

    344465

  • Contact name

    Alastair Jordan

  • Contact email

    a.jordan1@yorksj.ac.uk

  • Sponsor organisation

    York St John University

  • Clinicaltrials.gov Identifier

    ETH2324-0267, Institutional ethical approval

  • Duration of Study in the UK

    1 years, 1 months, 1 days

  • Research summary

    Peripheral Arterial Disease is a build-up of fatty deposits, called an atherosclerotic plaques, which narrow or completely block the blood vessels supplying blood to the lower limbs. A common symptom of peripheral arterial disease is intermittent claudication (IC) - a cramp-like pain in the musculature positioned ‘downstream’ of the plaque, most commonly in the calves. IC is brought on by walking, relieved by rest. Individuals with IC tend to have poorer physical function, balance and walking ability resulting in reduced quality of life when compared with age-matched controls. Individuals with IC demonstrate differences in walking gait. Differences in walking gait are responsible, in part, for an increased risk of falling the IC population when compared with age-matched population. Supervised exercise programmes (SEP) have been recommended for individuals with IC with increased physical function, walking distance until the onset of IC pain and improved quality of life cited as benefits. SEP-induced walking distances have been reported consistently, however more detailed gait analysis techniques offer deeper insights into SEP-induced changes in gait patterns and possible reduction in falls risk. The research team has developed a novel and evidence-based 12-week walking-based SEP service with York Hospital which aligns with NICE recommendations. The SEP is predominately walking over ground and walking through claudication pain, thus prolonging walking and increasing walking distances. The primary aim of this study is to determine the efficacy of the novel SEP on walking distances and changes in walking gait during pain-free, onset of pain and maximum IC pain walking using infra-red 3D optical motion analysis before and after the SEP.

  • REC name

    London - West London & GTAC Research Ethics Committee

  • REC reference

    24/PR/1152

  • Date of REC Opinion

    14 Nov 2024

  • REC opinion

    Further Information Favourable Opinion